A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

Key Inclusion Criteria:

1. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

2. Has histologically or cytologically confirmed cancer that meets criteria as definedin the protocol

3. Expansion Cohorts only: Is anti-programmed cell death protein-1 (PD-1)/programmedcell death ligand-1 (PD-L1) naïve, defined as never having previously been treatedwith a drug that targets the PD-1

4. Has at least 1 lesion that meets study criteria as defined in the protocol

5. Willing to provide tumor tissue from newly obtained biopsy (at a minimum corebiopsy) from a tumor site that has not been previously irradiated

6. Has adequate organ and bone marrow function as defined in the protocol

7. In the judgement of the investigator, has a life expectancy of at least 3 months

Key Exclusion Criteria:

1. Is currently participating in another study of a therapeutic agent

2. Has participated in any study of an investigational agent or an investigationaldevice within 4 weeks of the first administration of study drug as defined in theprotocol

3. Has received treatment with an approved systemic therapy within 4 weeks of the firstadministration of study drug or has not yet recovered (ie, grade 1 or baseline) fromany acute toxicities

4. Has received recent anti-epidermal growth factor receptor (EGFR) antibody therapy asdefined in the protocol

5. Has received radiation therapy or major surgery within 14 days of the firstadministration of study drug or has not recovered (ie, grade 1 or baseline) fromadverse events

6. Has received any previous systemic, non-immunomodulatory biologic therapy within 4weeks of first administration of study drug.

7. Has had prior anti-cancer immunotherapy within 5 half-lives prior to study drug asdefined in the protocol

8. Has second malignancy that is progressing or requires active treatment as defined inthe protocol

9. Has any condition requiring ongoing/continuous corticosteroid therapy (>10 mgprednisone/day or anti-inflammatory equivalent) within 1-2 weeks prior to the firstdose of study drug as defined in the protocol

10. Has ongoing or recent (within 5 years) evidence of significant autoimmune disease orany other condition that required treatment with systemic immunosuppressivetreatments as defined in the protocol

11. Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease,or spinal cord compression

12. Has encephalitis, meningitis, organic brain disease (eg, Parkinson's disease) oruncontrolled seizures within 1 year prior to the first dose of study drug

13. Has any ongoing inflammatory skin disease as defined in the protocol

NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply